Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT00229827 Terminated - Clinical trials for Ventricular Septal Defects

Optimal Timing for Repair of Left to Right Shunt Lesions

Start date: May 2005
Phase: N/A
Study type: Observational

The purpose of this study is to determine the optimal timing for repair of left-to-right shunt lesions such as ventricular septal defects and atrioventricular canals.

NCT ID: NCT00228891 Terminated - Clinical trials for Diabetes Mellitus, With Complications

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

Start date: February 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Diabetic neuropathy is a progressive complication causing serious problems in 25-40% of diabetic patients. Anecdotal reports have indicated improvement with pulsatile IV insulin in patients otherwise resistant to all conventional therapies. Significant complications produce painful peripheral dysesthesias, loss of sensation and gastroparesis. This study is designed to test the effectiveness of pulsatile insulin delivery on diabetic neuropathy.

NCT ID: NCT00227682 Terminated - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Sometimes when chemotherapy is given, it does not stop the growth of cancer cells. The cancer is said to be resistant to chemotherapy. Giving arsenic trioxide together with chemotherapy may reduce drug resistance and allow the cancer cells to be killed. Thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Giving arsenic trioxide together with thalidomide, dexamethasone, and ascorbic acid may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with thalidomide, dexamethasone, and ascorbic acid works in treating patients with relapsed or refractory multiple myeloma.

NCT ID: NCT00227032 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Start date: September 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with progressive glioblastoma multiforme.

NCT ID: NCT00225875 Terminated - Clinical trials for Autoimmune Thrombocytopenic Purpura

Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy

Start date: September 2003
Phase: Phase 2
Study type: Interventional

The goal of this study is to evaluate the clinical effectiveness of the rituximab at the adults with a chronic immune thrombocytopenic purpura (>=6 months of evolution) and severe (platelets <= 30x109/L) and candidate to a splenectomy. The objective is to obtain after a treatment by the rituximab a satisfactory response to one year, defined by a number of platelets higher than 50x109/L and at least 2 times superior with the persistent initial figure without treatment during one year after the end of the treatment.

NCT ID: NCT00225004 Terminated - Clinical trials for Previous or Actual Colles Fracture

Osteoporosis and Colles Fracture

Start date: July 2004
Phase: N/A
Study type: Observational

The primary purpose of the retrospective study is to determine the incidence of osteoporosis in women with previous Colles Fracture. Secondly, to determine to which extent Colles Fracture has led to a diagnosis and/or treatment of osteoporosis. The primary purpose of the prospective study is to determine the incidence of osteoporosis in women with an actual Colles Fracture. Secondly, to investigate the consistency between prospective and retrospective data.

NCT ID: NCT00220909 Terminated - Clinical trials for Patients Undergoing Elective Coronary Artery Bypass Graft

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine whether lansoprazole, administered intravenously, can protect patients undergoing cardiac surgery from the development of and/or progression of previously undetected acid/peptic disorders (erosive esophagitis, gastric ulcer, duodenal ulcer, diffuse gastritis, duodenitis) as measured by the Lanza score and LA classification for esophageal injury. The secondary objectives of this study are: 1. To determine if intravenous lansoprazole protects against the development of clinically important gastrointestinal bleeding in this population (overt bleeding or requiring blood transfusion). 2. To determine if intravenous lansoprazole maintains the intragastric pH above that for placebo throughout the study period.

NCT ID: NCT00219908 Terminated - Clinical trials for Relapsing-Remitting Multiple Sclerosis

Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

Start date: July 1999
Phase: Phase 2
Study type: Interventional

The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active relapsing-remitting multiple sclerosis.

NCT ID: NCT00217724 Terminated - Pain Clinical Trials

Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer

Start date: July 1999
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Nutritional supplements, such as glutamine, may prevent side effects caused by chemotherapy. PURPOSE: This randomized clinical trial is studying glutamine to see how well it works compared to placebo in preventing myalgia and/or arthralgia in patients who are receiving paclitaxel for cancer.

NCT ID: NCT00216008 Terminated - Clinical trials for Adenocarcinomas of the Gastroesophageal Junction

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out the effectiveness of the experimental combination of Docetaxel, Cisplatin, and radiation therapy administered prior to the surgical removal of your esophageal cancer.